A comparison of the effect of intravitreal dexamethasone implant on macular and branch retinal vein occlusion. A real life experience

Abstract

Purpose:

This study aimed to compare the effects of intravitreal dexamethasone (IVDx) implants on branch retinal vein occlusions (BRVOs) and macular vein occlusions (MVOs).

Methods:

Seventeen consecutive patients with MVO and 18 patients with BRVO, whose foveal thicknesses were greater than 300 µm, were recruited for this study. BRVO and MVO patients were diagnosed by means of fundus fluorescein angiography. Patients were treatment-naive. Initially, each patient in both the BRVO and MVO groups received an IVDx implant, and then a pro re nata IVDx regimen was initiated. Primary outcomes included VA gain, intraocular pressure (IOP) changes, macular ischemia, central macular thickness, retinal neovascularization, and number of IVDx injections. Follow-up time was 12 months.

Results:

The MVO group initially had significantly lower central macular thickness and a lower percentage of macular ischemia and systemic hypertension than those in the BRVO group (p = 0.001, 0.045, and 0.010, respectively). There was a statistically significant VA gain in both groups (p < 0.001), but the VA gain of the MVO group was greater than that of the BRVO group (p < 0.001). The mean total number of IVDx injections administered throughout the study period was significantly lower in the MVO group than in the BRVO group (1.3 ± 0.4 vs 2.0 ± 0.0; p = 0.001).

Discussion:

MVO and BRVO have different disease characteristics, and IVDx implants were more effective on the visual gain in patients with MVO than that of patients with BRVO who had higher numbers of IVDx injections.

Keywords

Macular vein occlusion branch retinal vein occlusion macular ischemia macular edema

Get full access to this article

View all access options for this article.

References

Rogers

McIntosh

Lim

, et al. Natural history of branch retinal vein occlusion: an evidence-based systematic review. Ophthalmology 2010; 117(6): 1094–1101.e5.

Paulus

Shuai

, et al. New developments in the classification, pathogenesis, risk factors, natural history, and treatment of branch retinal vein occlusion. J Ophthalmol 2017; 2017: 4936924.

Hayreh

Zimmerman

. Fundus changes in central retinal vein occlusion. Retina 2015; 35(1): 29–42.

Jaulim

Ahmed

Khanam

, et al. Branch retinal vein occlusion: epidemiology, pathogenesis, risk factors, clinical features, diagnosis, and complications. An update of the literature. Retina 2013; 33(5): 901–910.

Son

Kwak

Kim

, et al. Comparison of ranibizumab and bevacizumab for macular edema associated with branch retinal vein occlusion. Korean J Ophthalmol 2017; 31(3): 209–216.

Tao

Huang

Liu

, et al. Short-term effect of intravitreal conbercept injection on major and macular branch retinal vein occlusion. J Int Med Res 2019; 47(3): 1202–1209.

The Branch Vein Study Group. Argon laser photocoagulation for macular edema in branch vein occlusion. Am J Ophthalmol 1984; 98(3): 271–282.

Jonas

Paques

Monés

, et al. Retinal vein occlusions. Dev Ophthalmol 2010; 47: 111–135.

Karacorlu

Ozdemir

Karacorlu

. Resolution of serous macular detachment after intravitreal triamcinolone acetonide treatment of patients with branch retinal vein occlusion. Retina 2005; 25(7): 856–860.

10.

Iturralde

Spaide

Meyerle

, et al. Intravitreal bevacizumab (Avastin) treatment of macular edema in central retinal vein occlusion: a short-term study. Retina 2006; 26(3): 279–284.

11.

Clark

Boyer

Heier

, et al. Intravitreal aflibercept for macular edema following branch retinal vein occlusion: 52-week results of the VIBRANT study. Ophthalmology 2016; 123(2): 330–336.

12.

Haller

Bandello

Belfort

Jr , et al. Dexamethasone intravitreal implant in patients with macular edema related to branch or central retinal vein occlusion twelve-month study results. Ophthalmology 2011; 118(12): 2453–2460.

13.

Korobelnik

Kodjikian

Delcourt

, et al. Two year, prospective, multicenter study of the use of dexamethasone intravitreal implant for treatment of macular edema secondary to retinal vein occlusion in the clinical setting in France. Graefes Arch Clin Exp Ophthalmol 2016; 254(12): 2307–2318.

14.

Early Treatment Diabetic Retinopathy Study Research Group. Classification of diabetic retinopathy from fluorescein angiograms. ETDRS report number 11. Ophthalmology 1991; 98(Suppl. 5): 807–822.

15.

Aiello

Northrup

Keyt

, et al. Hypoxic regulation of vascular endothelial growth factor in retinal cells. Arch Ophthalmol 1995; 113(12): 1538–1544.

16.

Nauck

Karakiulakis

Perruchoud

, et al. Corticos-teroids inhibit the expression of the vascular endothelial growth factor gene in human vascular smooth muscle cells. Eur J Pharmacol 1998; 341(2–3): 309–315.

17.

Hayreh

Zimmerman

. Fundus changes in branch retinal vein occlusion. Retina 2015; 35(5): 1016–1027.

18.

Iida-Miwa

Muraoka

Iida

, et al. Branch retinal vein occlusion: treatment outcomes according to the retinal nonperfusion area, clinical subtype, and crossing pattern. Sci Rep 2019; 9(1): 1–12.

19.

Hayreh

Rojas

Podhajsky

, et al. Ocular neovascularization with retinal vascular occlusion-III. Incidence of ocular neovascularization with retinal vein occlusion. Ophthalmology 1983; 90(5): 488–506.

20.

Garweg

Zandi

. Retinal vein occlusion and the use of a dexamethasone intravitreal implant (Ozurdex®) in its treatment. Graefes Arch Clin Exp Ophthalmol 2016; 254(7): 1257–1265.

21.

Michaelides

Fraser-Bell

Hamilton

, et al. Macular perfusion determined by fundus fluorescein angiography at the 4-month time point in a prospective randomized trial of intravitreal bevacizumab or laser therapy in the management of diabetic macular edema (Bolt Study): Report 1. Retina 2010; 30(5): 781–786.